|
|
 Previous Article | Table of Contents | Next Article 
Growth factor requirements of childhood acute T-lymphoblastic leukemia:
correlation between presence of chromosomal abnormalities and ability to
grow permanently in vitro
R O'Connor, A Cesano, B Lange, J Finan, PC Nowell, SC Clark, SC Raimondi, G Rovera and D Santoli
Wistar Institute of Anatomy and Biology, Philadelphia, PA 19104.
Cells from 10 cases of childhood acute T-lymphoblastic leukemia (T-ALL)
were cultured in the presence of recombinant human interleukins (rhIL) or
colony-stimulating factors (CSF) to analyze their growth factor
requirements and differentiative potential. Although cells from most
leukemic samples displayed a short-term proliferative response to several
hematopoietic growth factors, only the ones featuring chromosomal
translocations could be established as permanent cell lines. Two cell lines
could be initiated only in the presence of IL-3 (TALL-103 and TALL-106),
one in granulocyte-macrophage CSF (GM-CSF) (TALL-101), and one in IL-2
(TALL-104); only one cell line (TALL-105) was originated in the absence of
growth factors. The TALL-101 and TALL- 103 cell lines, derived from very
immature T-ALL cases, underwent growth factor-dependent phenotypic
conversion (lymphoid to myeloid). However, the T-cell receptor
rearrangement and karyotype of the original leukemic clones were retained.
In contrast, the TALL-104, - 105, and -106 cell lines which originated from
more mature T-ALL cases, maintained a T-lymphoblastic phenotype regardless
of the growth factors in which they were expanded. These data demonstrate
in vitro the aggressive nature of T-ALL cases bearing chromosomal
abnormalities, and indicate that the lineage commitment of the malignant
clone depends on its stage of maturation in T-cell ontogeny.
Volume 77,
Issue 7,
pp. 1534-1545,
04/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Brando, S. Mukhopadhyay, E. Kovacs, R. Medina, P. Patel, T. L. Catina, K. S. Campbell, and D. Santoli
Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104
J. Leukoc. Biol.,
August 1, 2005;
78(2):
359 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Gomez, S. B. Read, L. E. Gerschenson, D. Santoli, A. Zweifach, and C. A. Kruse
Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors
Neuro-oncol,
April 1, 2004;
6(2):
83 - 95.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. A. Kruse, S. Visonneau, B. K. Kleinschmidt-DeMasters, C. J. Gup, G. G. Gomez, D. B. Paul, and D. Santoli
The Human Leukemic T-Cell Line, TALL-104, Is Cytotoxic to Human Malignant Brain Tumors and Traffics through Brain Tissue: Implications for Local Adoptive Immunotherapy
Cancer Res.,
October 1, 2000;
60(20):
5731 - 5739.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Visonneau, A. Cesano, D. L. Porter, S. L. Luger, L. Schuchter, M. Kamoun, M. H. Torosian, K. Duffy, C. Sickles, E. A. Stadtmauer, et al.
Phase I Trial of TALL-104 Cells in Patients with Refractory Metastatic Breast Cancer
Clin. Cancer Res.,
May 1, 2000;
6(5):
1744 - 1754.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Geoerger, C.-B. Tang, A. Cesano, S. Visonneau, S. Marwaha, K. D. Judy, L. N. Sutton, D. Santoli, and P. C. Phillips
Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts
Neuro-oncol,
April 1, 2000;
2(2):
103 - 113.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Cesano, S. Visonneau, S. Deaglio, F. Malavasi, and D. Santoli
Role of CD38 and Its Ligand in the Regulation of MHC-Nonrestricted Cytotoxic T Cells
J. Immunol.,
February 1, 1998;
160(3):
1106 - 1115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
